ENLIVEN THERAPEUTICS, INC.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2018 | — | — | $7.4M |
| Mar 2019 | — | — | $48.9M |
| Jun 2019 | — | — | $45.2M |
| Sep 2019 | — | — | $17.1M |
| Dec 2019 | $4.4M | $33.3M | $4.9M |
| Mar 2020 | $5.1M | $110.3M | $86.7M |
| Jun 2020 | $5.0M | $111.3M | $54.7M |
| Sep 2020 | $5.5M | $100.2M | $34.2M |
| Dec 2020 | $6.4M | $90.8M | $47.7M |
| Mar 2021 | $6.1M | $81.7M | $53.4M |
| Jun 2021 | $7.5M | $72.5M | $48.0M |
| Sep 2021 | $7.7M | $107.0M | $75.3M |
| Dec 2021 | $7.6M | $93.6M | $48.3M |
| Mar 2022 | $9.2M | $81.6M | $99.9M |
| Jun 2022 | $3.3M | $64.7M | $92.5M |
| Sep 2022 | $1.8M | $59.1M | $86.2M |
| Dec 2022 | $10.4M | $83.3M | $75.5M |
| Mar 2023 | $11.5M | $302.9M | $292.1M |
| Jun 2023 | $9.5M | $288.5M | $125.7M |
| Sep 2023 | $12.3M | $274.0M | $73.8M |
| Dec 2023 | $26.0M | $271.9M | $100.1M |
| Mar 2024 | $25.1M | $342.8M | $149.2M |
| Jun 2024 | $22.1M | $327.0M | $96.9M |
| Sep 2024 | $17.0M | $305.4M | $100.6M |
| Dec 2024 | $15.9M | $325.8M | $124.1M |
| Mar 2025 | $14.3M | $302.6M | $101.7M |
| Jun 2025 | $15.4M | $503.9M | $119.4M |
| Sep 2025 | $14.8M | $490.9M | $101.7M |
| Dec 2025 | $16.6M | $476.2M | $98.9M |
| Mar 2026 | $11.5M | $464.9M | $132.2M |
| Jun 2026 | $15.1M | $910.2M | $135.5M |